Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Ludwig Cancer Research have leveraged functional genomics to suppress the function of the mutant histones responsible for driving 80% of incurable childhood brain tumours.

Doctor and a child with cancer

The H3K27M oncogenic histone mutation drives around 80% of incurable childhood brain tumours, known as diffuse midline gliomas. Alan Jiao and researchers in Professor Yang Shi’s research group show that the enzyme ubc-20 is the major enzyme responsible for generating di-ubiquinated histone H2B. These results reveal a previously unstudied ubiquitination pathway as a potential novel therapeutic target in incurable paediatric gliomas.

By isolating various H3K27M suppressor mutations, all of which at least partially restore H3K27Me, the global loss of H3K27 tri-methylation. Most of the suppressors mapped to the same histone H3.3 gene, in which the K27M mutation was originally introduced and are predicted to impair PRC2-nucleosome interactions. The group further mapped a single extragenic suppressor to ubc-20 and demonstrated its role as the major enzyme responsible for generating di-ubiquinated histone H2B.

To learn more about this work, read the full article on the PNAS website: https://www.pnas.org/doi/10.1073/pnas.2416614121?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed